Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Próximos ensayos clínicos
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied...Aún no reclutandoHabilidades motoras | Saludable | Función ejecutiva
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCAún no reclutandoCarcinoma anal de células escamosas
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaAún no reclutandoArtritis Reumatoide | Enfermedad articular degenerativa de la rodillaItalia
-
University of Wisconsin, MadisonAlkermes, Inc.Aún no reclutando
-
Virginia Commonwealth UniversityAún no reclutandoEdema cerebral | Necrosis por radiaciónEstados Unidos
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount...Aún no reclutandoKetamina | IRMf | Depresión - Trastorno Depresivo Mayor | rTMS | Depresión resistente al tratamiento (TRD)Estados Unidos
-
Weill Medical College of Cornell UniversityBD2 LLCAún no reclutandoIRMf | Trastorno Bipolar (TB) | rTMS | Depresión bipolar 1Estados Unidos
-
Xentria, Inc.Aún no reclutando
-
Yale UniversityNational Institute of Mental Health (NIMH)Aún no reclutando
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeReclutamientoFeocromocitoma | Feocromocitoma/Paraganglioma | Feocromocitoma Metastásico | Feocromocitoma Maligno | Feocromocitoma y paraganglioma (PPGL)Reino Unido
-
Carl Zeiss Meditec-Dublin CoCeReclutamientoMembrana epirretiniana | Enfermedad de la retina | Degeneración macular seca relacionada con la edad | Anomalía vitreorretiniana | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium (RPE) AtrophyEstados Unidos
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityReclutamientoCLDN18.2 Tumores sólidos positivosPorcelana
Clinical Research Jobs
-
Czechia - Brno
-
Belgium - Leuven
-
United Kingdom - Tranent
-
Romania - Bucharest
-
United StatesCanada - Québec - Quebec
-
United Kingdom - Guildford
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China
